Home › Research › Treatments
Alzheimer's Disease: Silent Erosion of Memory - From Discovery to Modern Crisis and the Quest for a Cure
Rasheed M. A. Q. Jamhour, Haya J. Ayyal Salman, Mohammed Alshammari, Afaf F. Almuqati, Mohamed H. Fayed, Ghassab M. Al‐Mazaideh. Current Alzheimer Research, 2026-05-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder characterized by a decline in cognitive abilities and memory impairment, representing the most common form of dementia worldwide. First described by Alois Alzheimer in 1906, AD continues to pose significant global health and socioeconomic challenges, with incidence anticipated to exceed 14 million cases by 2060. Despite decades of investigation, the specific pathophysiology -comprising multifactorial mechanisms such as genetic predisposition, environmental influences, lifestyle factors, amyloid-β (Aβ) plaques, neurofibrillary tangles, tau pathology, as well as vascular disease - remains incompletely understood. This review provides a comprehensive summary of the current knowledge regarding these mechanisms, and it explores the field's new therapeutic modalities, such as monoclonal antibodies, ultrasound-based treatments, and novel diagnostic tools based on biomarkers. It also discusses the socioeconomic burden of AD and regional challenges in the Middle East, as well as the impact of the COVID-19 pandemic on dementia care. While many of AD's underlying causes are aggressive and difficult to treat, new research in genetics, natural compounds, and groundbreaking therapies offers hope for better diagnosis and treatment. Above all, this study emphasizes the importance of having more effective chemotherapeutic or radiological approaches for ADs, as well as a robust medical system capable of providing these treatments to the patients.
What this study adds
Evidence grade: Low
This review summarizes proposed Alzheimer's mechanisms and new therapeutic modalities such as monoclonal antibodies, ultrasound-based treatments, and biomarker-based diagnostics. It reports no specific treatment result and states that the underlying causes remain incompletely understood, so no cure or prevention is established.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jamhour, R. M. A. Q., Salman, H. J. A., Alshammari, M., Almuqati, A. F., Fayed, M. H., & Al‐Mazaideh, G. M. (2026). Alzheimer's Disease: Silent Erosion of Memory - From Discovery to Modern Crisis and the Quest for a Cure. Current Alzheimer Research. https://doi.org/10.2174/0115672050423446251215051844
Vancouver
Jamhour RMAQ, Salman HJA, Alshammari M, Almuqati AF, Fayed MH, Al‐Mazaideh GM. Alzheimer's Disease: Silent Erosion of Memory - From Discovery to Modern Crisis and the Quest for a Cure. Current Alzheimer Research. 2026. doi:10.2174/0115672050423446251215051844.
BibTeX
@article{jamhour2026-738be83b,
author = {Jamhour, Rasheed M. A. Q. and Salman, Haya J. Ayyal and Alshammari, Mohammed and Almuqati, Afaf F. and Fayed, Mohamed H. and Al‐Mazaideh, Ghassab M.},
title = {{Alzheimer's Disease: Silent Erosion of Memory - From Discovery to Modern Crisis and the Quest for a Cure}},
journal = {Current Alzheimer Research},
year = {2026},
doi = {10.2174/0115672050423446251215051844},
url = {https://doi.org/10.2174/0115672050423446251215051844}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- First described by Alois Alzheimer in 1906, AD continues to pose significant global health and socioeconomic challenges, with incidence anticipated to exceed 14 million cases by 2060.
Why it matters
This review summarizes proposed Alzheimer's mechanisms and new therapeutic modalities such as monoclonal antibodies, ultrasound-based treatments, and biomarker-based diagnostics. It reports no specific treatment result and states that the underlying causes remain incompletely understood, so no cure or prevention is established.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current Alzheimer Research) |
| Journal's citation record | 1 / 4 | Current Alzheimer Research: journal h-index 119 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Ghassab Mohammad Al-Mazaideh: h-index 14 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Fayoum University: institution h-index 178 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 3 countries |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.